Abstract
Background and Aims: The disease course of microscopic colitis [MC] is considered chronic but benign. However, this assumption is based on mainly retrospective studies, reporting on incomplete follow-up of selective cohorts. Systematic, prospective and unbiased data to inform patients and healthcare professionals on the expected course of the disease and real-life response to therapy are warranted.Methods: A prospective, pan-European, multi-centre, web-based registry was established. Incident cases of MC were included. Data on patient characteristics, symptoms, treatment and quality of life were systematically registered at baseline and during real-time follow-up. Four disease course phenotypes were discriminated and described.Results: Among 381 cases with complete 1-year follow-up, 49% had a chronic active or relapsing disease course, 40% achieved sustained remission after treatment and 11% had a quiescent course. In general, symptoms and quality of life improved after 3 months of follow-up. A relapsing or chronic active disease course was associated with significantly more symptoms and impaired quality of life after 1 year.Conclusions: A minority of MC patients follow a quiescent disease course with spontaneous clinical improvement, whereas the majority suffer a chronic active or relapsing disease course during the first year after diagnosis, with persisting symptoms accompanied by a significantly impaired quality of life.
Original language | English |
---|---|
Pages (from-to) | 1174-1183 |
Number of pages | 10 |
Journal | Journal of Crohn's & Colitis |
Volume | 15 |
Issue number | 7 |
DOIs | |
Publication status | Published - 1 Jul 2021 |
Keywords
- Microscopic colitis
- disease course
- prospective cohort study
- disease activity
- prognosis
- treatment
- TERM-FOLLOW-UP
- COLLAGENOUS COLITIS
- DOUBLE-BLIND
- LYMPHOCYTIC COLITIS
- CLINICAL PRESENTATION
- PLACEBO
- RISK
- BUDESONIDE
- LOPERAMIDE
- HISTOPATHOLOGY